SHR3824 is a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this multiple-dose study the investigators evaluated the safety, tolerability and PK/PD profiles of SHR3824 in healthy subjects.

Inclusion criteria:

• Chinese male and female subjects aged 18 to 45 years.
• BMI:18 -25 kg/m2.
• Healthy according to medical history, physical examination findings, 12-lead ECG findings, and clinical laboratory evaluations.

Exclusion criteria:

• History of or current clinically significant medical illness as determined by the Investigator.
• History of clinically significant allergies, especially known hypersensitivity or intolerance to lactose.
• Pregnancy or breastfeeding . Significant acute or chronic medical illness, including renal impairment, or recent surgery.
• Donation of blood or plasma within the 4 weeks prior to the start of the study or acceptance of blood transfusion within 8 weeks.